Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives

Mattia Galli, Italo Porto, Felicita Andreotti, Domenico D'Amario, Rocco Vergallo, Roberta Della Bona, Filippo Crea

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)


Anticoagulant therapy during the acute phase of non-ST elevation acute coronary syndromes (NSTE-ACS) is strongly recommended by current international guidelines. Evidence supporting the use of anticoagulant therapy in the early phase of NSTE-ACS however, is based on dated trials mostly performed in the nineties and recent randomised clinical trials (RCTs), performed during the last 15 years, clearly evidence a dichotomy in the investigation of antiplatelet and anticoagulant strategies. Many innovations have since occurred in the diagnosis and management of NSTE-ACS. Since a RCT evaluating the efficacy of anticoagulant therapy versus placebo in a contemporary setting of NSTE-ACS management is lacking, we provide a systematic review of 1) the randomised data for ATT in the early phase of NSTE-ACS; 2) modern international guidelines, and 3) contemporary clinical practice data. The results are analysed and potential treatment and research strategies are proposed. (c) 2018 Elsevier B.V. All rights reserved.
Lingua originaleEnglish
pagine (da-a)39-45
Numero di pagine7
RivistaInternational Journal of Cardiology
Stato di pubblicazionePubblicato - 2019


  • Acute Coronary Syndrome
  • Anticoagulants
  • Disease Management
  • Early phase
  • Electrocardiography
  • Humans
  • Modern management
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Thrombolytic Therapy
  • Time Factors


Entra nei temi di ricerca di 'Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives'. Insieme formano una fingerprint unica.

Cita questo